Biogenerics: The World Market for Biosimilars

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Trends Affecting the Market
• Market Outlook

CHAPTER TWO: INTRODUCTION AND OVERVIEW

• Biogenerics Overview
• Biopharmaceutical Industry and Approval Process
  • Genetic Engineering Patent Approval
• Regulations for Biopharmaceuticals
• History of the Prescription Generic Pharmaceuticals Industry
• History of the Generic Approval Process
• Regulation of Prescription Generic Pharmaceuticals
• Biopharmaceuticals
• Areas of Treatment for Biopharmaceuticals

CHAPTER THREE: BIOGENERIC PHARMACEUTICALS FOR EXPIRED BIOLOGIC PATENTS

• Market Size and Growth
  • Non-U.S. Market

CHAPTER FOUR: BIOGENERIC PHARMACEUTICALS FOR FUTURE EXPIRED BIOLOGIC PATENTS

• Market Size and Growth
  • World Market
  • Non-U.S. Market

CHAPTER FIVE: ISSUES AND TRENDS

• Overview
• Worldwide Regulatory and Legislative Issues
  • Europe
  • United States
  • Rest of World
• Asia and Biogenerics
• Scientific Issues
• Patent Issues
• Pricing Issues
• Barriers to Entry
• Innovator Strategies and Challenges
• Bulk Suppliers and Contract Manufacturing
• Bioequivalence Issues
• International Issues
• Low Cost Branded HGH
• Biogenerics and Health-Care Spending
• Intellectual Property

CHAPTER SIX: MARKET SUMMARY

• Total Market Size and Forecast
• Competitor Analysis

CHAPTER SEVEN: CORPORATE PROFILES

• Analiza, Inc
• Apotex, Inc.
• Barr Laboratories, Inc.
• Biogenerix Ag
• Biocon Ltd .
• BioPartners GmbH
• Cangene Corporation
• Dr. Reddy' s Laboratories Limited
• Dragon Pharmaceuticals, Inc.
• GeneMedix PLC
• Hospira, Inc.
• Microbix Biosystems, Inc.
• Momenta Pharmaceuticals Inc
• Phage Biotechnology Corp
• Sandoz
• Sicor, Inc.
• STADA Arzneimittel AG
• TEVA Pharmaceutical Industries, Ltd.
• Watson Pharmaceuticals, Inc.

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Total World Biogenerics Market Potential 2006-2012
• Figure 1-1: The World Market Potential for BioGeneric Drugs by Revenues 2006-2012

INTRODUCTION AND OVERVIEW

• Table 2-1: Scientific Differences of Pharmaceuticals and Biopharmaceuticals

CHAPTER THREE: BIOGENERIC PHARMACEUTICALS FOR EXPIRED BIOLOGIC PATENTS

• Table 3-2: Marketed Biopharmaceuticals with Expired Patents
• Table 3-3: Total World Biogenerics Market Potential 2006-2012, Products with Expired Patents
• Table 3-4: Total U.S. Biogenerics Market Potential 2006-2012, Products with Expired Patents Table 3-5: Total Non-U.S. Biogenerics Market Potential 2006-2012, Products with Expired Patents

CHAPTER FOUR: BIOGENERIC PHARMACEUTICALS FOR FUTURE EXPIRED BIOLOGIC PATENTS

• Table 4-1: Marketed Biopharmaceuticals with Active Patents
• Table 4-2: Total World Biogenerics Market Potential 2006-2012, Products with Active Patents
• Table 4-3: Total U.S. Biogenerics Market Potential 2006-2012, Products withActive Patents
• Table 4-4: Total Non-U.S. Biogenerics Market Potential 2006-2012, Products with Active Patents

CHAPTER FIVE: ISSUES AND TRENDS

• Table 5-1: Estimates of Treatment Cost Per Patient of Selected Biopharmaceuticals

CHAPTER SIX: MARKET ANALYSIS

• Table 6-1: Total World Biogenerics Market Potential 2006-2012
• Table 6-2: The World Market Potential for BioGeneric Drugs by Patent Segment 2006-2012
• Figure 6-1 Total World Biogenerics Market Potential 2006-2012 (Active, Expired)
• Figure 6-2 The World Market Potential for BioGeneric Drugs by Patent Segment (Active, Expired) 2006-2012